Evolution of HER-2 Targeted Therapies

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • The development of the monoclonal antibody trastuzumab (Herceptin):
    • Has revolutionized the treatment of patients with HER-2-positive breast cancer
  • The exact mechanism of action of trastuzumab remains unclear:
    • It is postulated that its action includes:
      • Antibody-dependent cellular toxicity
      • Inhibition of cell cycle progression
        • Anti-angiogenic effects
  • The use of trastuzumab was first approved by the Food and Drug Administration (FDA) in 1998:
    • For the treatment of HER-2-positive metastatic disease:
      • Since that time, drug testing progressed to the adjuvant and neoadjuvant settings
  • Today, trastuzumab is regarded as the standard of care for patients with HER-2-positive breast cancer
  • Other agents include:
    • The small-molecule tyrosine kinase inhibitor lapatinib and newer drugs, including pertuzumab, trastuzumab-emtansine, neratinib, and ertumaxomab

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s